You would be studying the links between stress and illness.
Increasing ocean acidity impact the mechanism of natural selection by
leading to increased random mutations and unfavorable traits.
<h3>Effects of Ocean acidity</h3>
Ocean acidity is harmful to organisms present and gives rise to the following:
This could be as a result of excess Carbon dioxide or acidic contents in the
ocean. This negatively impacts organisms and alters the genetic constituent
thereby leading to mutations and passing on of unfavorable traits to
offsprings.
Read more about Ocean acidity here brainly.com/question/999152
Answer:
Evolution in humans is happening spontaneously and the development of species can improve the capability of offspring and the intelligence of species. All animals today are evolutionary, we came from bacteria to being are millions of times the size of that organism with millions of years going through evolution. We have gone from splitting our cells to make more, to creating life to another to do the same.
Explanation:
The peripheral nervous system is made up of two systems; the somatic nervous system controls muscle movement and the autonomic nervous system connects with internal organs.
Answer:
Phase III
Explanation:
The given condition fall in the trial phase (Phase III) of cinical study which aims to:
- Determine drug's effectiveness (primary goal)
- Determine long-term drug safety
- Confirm findings
In Phase III, randomised, double-blind, placebo-controlled, parallel group study is majorly to evaluate the efficacy and safety of placebo in episodic migraine prevention in children (6 to < 12 years of age) and adolescents (12 to < 18 years of age).
The trial consists of four phases: screening; double-blind therapy period for 24 weeks in which placebo or Erenumab is given to subject as dose 1, dose 2 or dose 3 (based on the participant's body weight) once a month via subcutaneous injection; optional dose level blinded extension phase (40 weeks) which involves subjects recieve dose1, 2 and 3 of placebo, and at last it follows a safety follow-up phase for 12 weeks (after 16 weeks of the last dose of investigational drug).
Hence, the clinical phase is phase III.
